A Phase 2A, Single-Center, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy of an Anti-Inflammatory Agent in Patients With Sinusitis
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 43
- 主要终点
- Sinus CT Scan Scores by Lund-Mackay Scores
研究概览
简要总结
To evaluate the efficacy of an anti-inflammatory agent compared with placebo in relieving signs and symptoms of disease in patients with sinusitis.
详细描述
This is a Phase 2a, single-center, randomized, placebo-controlled, double-blind study that includes 12 weeks of treatment with experimental drug anti-inflammatory agent or placebo TID administered orally.
All subjects will be ≥18 years, have sinusitis with persistent symptoms despite standard of care treatment, and have failed a course of steroids in the past.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Females must have a negative urine pregnancy test at screening unless documented to have a hysterectomy or be postmenopausal.
排除标准
- •Inability or unwillingness of a participant to give written informed consent or comply with study protocol
- •Use of any investigational drugs within 30 days of screening.
- •Acute infection needing antibiotic treatment at screening.
研究组 & 干预措施
AZ Compound
40 mg 12 weeks TID po
干预措施: AZ compound (Drug)
Placebo
40 mg 12 weeks TID po
干预措施: Intranasal corticosteroid (Drug)
AZ Compound
40 mg 12 weeks TID po
干预措施: Collection of Biological Specimens (Other)
AZ Compound
40 mg 12 weeks TID po
干预措施: Intranasal corticosteroid (Drug)
Placebo
40 mg 12 weeks TID po
干预措施: Placebo (Drug)
Placebo
40 mg 12 weeks TID po
干预措施: Collection of Biological Specimens (Other)
结局指标
主要结局
Sinus CT Scan Scores by Lund-Mackay Scores
时间窗: Baseline and Week 12
Measurement of secondary outcome: sinus CT scan scores by Lund-Mckay scores. We measured sinus radiographic severity with Lund-Mackay scores of 0 to 24. 0 was the least severe and 24 was the most severe. This secondary outcomes included change in radiographic severity of sinus disease, as measured by sinus CT scan scores at baseline and 12 weeks in the AZD1981 group vs. the placebo group.
BSIT (Brief Smell Identification Test)
时间窗: Baseline and Week 12
Measurement of secondary outcome- BSIT (brief smell identification test) is a 12-item test measuring sense of smell. This is a multiple choice test with one correct answer out of four possible answer choices. This test features distinct types of smells. Minimum score: 0/12, which indicates that none of the correct answers were chosen on the 12-item test. Maximum score: 12/12, which indicates that all of the correct answers were chosen on the 12-item test. The higher the score, the better the outcome. Only one out of the four possible answer choices for each multiple choice question is correct. There are no subscales. This secondary outcome measures sense of smell by Brief Smell Identification Test (B-SIT) at baseline (visit 1) and 12 weeks (visit 5) in the AZD1981 group vs. the placebo group.
TOTAL POLYP SCORE (TPS)
时间窗: Baseline and Week 12
Measure Description: Measurement of Primary outcome- 0-4 scale in each nostril, total is 8. The total polyp score is the sum of the right and left nasal polyp score. Maximum is 8, minimum is 0. Higher score indicates worse disease. 0 =No polyps 1=Small polyps in the middle meatus not reaching below the inferior border of the middle turbinate 2=Polyps reaching the lower border of the middle turbinate or polyp medial to the middle turbinate 3 = Large polyps reaching the lower border of the inferior turbinate 4 =Large polyps causing complete obstruction. The primary outcome measured change in polyp size and secondary outcomes included change in radiographic severity of sinus disease, quality of life, and nasal symptoms as measured by Sino Nasal Outcome Test-22 (SNOT-22) and sense of smell by Brief Smell Identification Test (B-SIT) at 12 weeks in the AZD1981 group vs. the placebo. These were done at the baseline visit and the Week 12 visit.
次要结局
- SNOT-22 (Sino-Nasal Outcome Test-22) Score(Baseline and Week 12)
- Visual Analog Scale (VAS)(Baseline and Week 12)
研究者
Anju Peters
Principal Investigator
Northwestern University
